JP2018508573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508573A5 JP2018508573A5 JP2017560892A JP2017560892A JP2018508573A5 JP 2018508573 A5 JP2018508573 A5 JP 2018508573A5 JP 2017560892 A JP2017560892 A JP 2017560892A JP 2017560892 A JP2017560892 A JP 2017560892A JP 2018508573 A5 JP2018508573 A5 JP 2018508573A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- antibody
- disease
- fully human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000003942 amyloidogenic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562116353P | 2015-02-13 | 2015-02-13 | |
| US62/116,353 | 2015-02-13 | ||
| PCT/US2016/017713 WO2016130898A2 (en) | 2015-02-13 | 2016-02-12 | Antibody therapeutics that bind ctla4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000465A Division JP2021054857A (ja) | 2015-02-13 | 2021-01-05 | Ｃｔｌａ４に結合する抗体医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508573A JP2018508573A (ja) | 2018-03-29 |
| JP2018508573A5 true JP2018508573A5 (enExample) | 2019-03-22 |
| JP6917902B2 JP6917902B2 (ja) | 2021-08-11 |
Family
ID=56614957
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560892A Active JP6917902B2 (ja) | 2015-02-13 | 2016-02-12 | Ｃｔｌａ４に結合する抗体医薬 |
| JP2021000465A Withdrawn JP2021054857A (ja) | 2015-02-13 | 2021-01-05 | Ｃｔｌａ４に結合する抗体医薬 |
| JP2022061876A Withdrawn JP2022084942A (ja) | 2015-02-13 | 2022-04-01 | Ｃｔｌａ４に結合する抗体医薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000465A Withdrawn JP2021054857A (ja) | 2015-02-13 | 2021-01-05 | Ｃｔｌａ４に結合する抗体医薬 |
| JP2022061876A Withdrawn JP2022084942A (ja) | 2015-02-13 | 2022-04-01 | Ｃｔｌａ４に結合する抗体医薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10202453B2 (enExample) |
| EP (3) | EP4151231A1 (enExample) |
| JP (3) | JP6917902B2 (enExample) |
| KR (1) | KR20180006367A (enExample) |
| CN (2) | CN108271359B (enExample) |
| AR (1) | AR103675A1 (enExample) |
| AU (2) | AU2016219170B2 (enExample) |
| CA (1) | CA2976446A1 (enExample) |
| ES (1) | ES2882157T3 (enExample) |
| IL (3) | IL292578A (enExample) |
| MX (3) | MX384026B (enExample) |
| TW (1) | TW201636369A (enExample) |
| WO (2) | WO2016130898A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| RU2711380C2 (ru) | 2015-07-16 | 2020-01-16 | Байоксэл Терапьютикс, Инк. | Новый подход к лечению рака с применением иммуномодуляции |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| JP6976322B2 (ja) * | 2016-10-10 | 2021-12-08 | クラウン バイオサイエンス，インコーポレイテッド（タイツァン） | 新規抗ｃｔｌａ４抗体 |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| EP3585430A4 (en) * | 2017-02-21 | 2020-12-09 | REMD Biotherapeutics, Inc. | TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4) |
| US20220411506A1 (en) * | 2017-03-15 | 2022-12-29 | Suzhou Galaxy Biopharma Co., Ltd. | Ctla4 antibody, pharmaceutical composition and use thereof |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019120232A1 (en) * | 2017-12-20 | 2019-06-27 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019232265A1 (en) * | 2018-05-31 | 2019-12-05 | Sorrento Therapeutics, Inc. | Drug delivery methods targeting the lymphatic system |
| WO2019236681A1 (en) * | 2018-06-05 | 2019-12-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rapid production, expansion, and increased purity of car-t cells using beads with protein l |
| CN110760002A (zh) * | 2018-07-25 | 2020-02-07 | 南京金斯瑞生物科技有限公司 | 人源化抗人ctla4单克隆抗体及其制备方法和用途 |
| BR112021008060A2 (pt) * | 2018-10-31 | 2021-11-23 | Bioatla Inc | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020139926A2 (en) | 2018-12-26 | 2020-07-02 | Akrevia Therapeutics Inc. | Anti-ctla4 antibodies and methods of use thereof |
| AU2019413366B2 (en) | 2018-12-27 | 2025-06-05 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US12435148B2 (en) | 2019-07-12 | 2025-10-07 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind CXCR4 to modulate cellular function |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| WO2021170750A1 (en) | 2020-02-28 | 2021-09-02 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| AU2021299338A1 (en) * | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| US20240182571A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| CN119907811A (zh) | 2022-08-02 | 2025-04-29 | Ose免疫疗法公司 | 针对cd28的多功能分子 |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| AU772676B2 (en) * | 1998-12-23 | 2004-05-06 | Amgen Fremont Inc. | Human monoclonal antibodies to CTLA-4 |
| AU784012B2 (en) * | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| WO2001054732A1 (en) * | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| PT2275449T (pt) * | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| US7452535B2 (en) * | 2002-04-12 | 2008-11-18 | Medarex, Inc. | Methods of treatment using CTLA-4 antibodies |
| RU2377253C2 (ru) * | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| AU2005225227A1 (en) * | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-CTLA-4 antibodies |
| PT2314621E (pt) * | 2004-05-27 | 2014-06-23 | Crucell Holland Bv | Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações |
| EP1863532A1 (en) * | 2005-03-23 | 2007-12-12 | Pfizer Products Incorporated | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| CN101146552A (zh) * | 2005-03-23 | 2008-03-19 | 辉瑞产品有限公司 | 用ctla4抗体和激素疗法治疗前列腺癌 |
| EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| CN102203132A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| MX352889B (es) * | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| SG10201705787VA (en) * | 2012-09-27 | 2017-08-30 | Merus Nv | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| US20170233476A1 (en) * | 2016-02-12 | 2017-08-17 | Sorrento Therapeutics, Inc. | Antibody Therapeutics That Bind CTLA4 |
-
2016
- 2016-02-12 CN CN201680015455.8A patent/CN108271359B/zh active Active
- 2016-02-12 US US15/043,157 patent/US10202453B2/en active Active
- 2016-02-12 AR ARP160100391A patent/AR103675A1/es unknown
- 2016-02-12 EP EP22189031.2A patent/EP4151231A1/en not_active Withdrawn
- 2016-02-12 JP JP2017560892A patent/JP6917902B2/ja active Active
- 2016-02-12 WO PCT/US2016/017713 patent/WO2016130898A2/en not_active Ceased
- 2016-02-12 ES ES16749944T patent/ES2882157T3/es active Active
- 2016-02-12 AU AU2016219170A patent/AU2016219170B2/en not_active Ceased
- 2016-02-12 CN CN202111220911.1A patent/CN114014930A/zh active Pending
- 2016-02-12 EP EP16749944.1A patent/EP3256165B1/en active Active
- 2016-02-12 KR KR1020177025857A patent/KR20180006367A/ko not_active Ceased
- 2016-02-12 WO PCT/US2016/017859 patent/WO2016130986A1/en not_active Ceased
- 2016-02-12 CA CA2976446A patent/CA2976446A1/en not_active Abandoned
- 2016-02-12 MX MX2017010412A patent/MX384026B/es unknown
- 2016-02-12 EP EP21183628.3A patent/EP3949984A1/en not_active Withdrawn
- 2016-02-12 IL IL292578A patent/IL292578A/en unknown
- 2016-02-15 TW TW105104408A patent/TW201636369A/zh unknown
-
2017
- 2017-08-11 IL IL253963A patent/IL253963B/en unknown
- 2017-08-11 MX MX2021007947A patent/MX2021007947A/es unknown
- 2017-08-11 MX MX2022011935A patent/MX2022011935A/es unknown
-
2019
- 2019-01-08 US US16/243,016 patent/US11155623B2/en not_active Expired - Fee Related
-
2021
- 2021-01-05 JP JP2021000465A patent/JP2021054857A/ja not_active Withdrawn
- 2021-06-23 IL IL284336A patent/IL284336B/en unknown
- 2021-09-22 US US17/482,138 patent/US20220002415A1/en not_active Abandoned
- 2021-12-08 AU AU2021282431A patent/AU2021282431A1/en not_active Abandoned
-
2022
- 2022-04-01 JP JP2022061876A patent/JP2022084942A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508573A5 (enExample) | ||
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
| CY1123138T1 (el) | Κυτταροτοξικες πρωτεϊνες που περιλαμβανουν περιοχες δεσμευσης στοχευσης-κυtταρων και περιοχες α υπομοναδας τοξινης shiga για επιλεκτικη θανατωση συγκεκριμενων κυτταρικων τυπων | |
| JP2018508509A5 (enExample) | ||
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| PH12021551401A1 (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| SA523440622B1 (ar) | أجسام مضادة | |
| EA201691836A1 (ru) | Антитела к mcam и соответствующие способы их применения | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| CY1123926T1 (el) | Αντισωματα κατα της τρανσγλουταμινασης 2 | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| EP3773632A4 (en) | Methods of treating egfrviii expressing glioblastomas | |
| JP2018529661A5 (enExample) | ||
| EA202190647A1 (ru) | Антитела к klrg1 | |
| MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
| MX2023010661A (es) | Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. | |
| EA202190495A1 (ru) | Антитела против pd-l1 человека | |
| JP2020521761A5 (enExample) | ||
| EA201990559A1 (ru) | Комбинированная терапия | |
| EA200702634A1 (ru) | Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения | |
| EP4419129A4 (en) | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE |